New Delhi, April 24 -- Gujarat Themis Biosyn shares jumped over 15% on Friday, 24 April as the company prepares to acquire a range of anti-tuberculosis (TB) and anti-infective brands from Sanofi, the French-based parent company of the Sanofi group.

According to a stock exchange announcement made late Thursday, the firm has signed an Asset Purchase Agreement to buy 13 well-established branded generic products that have a strong market presence in over 55 countries across Europe, the Middle East, and Africa, for Euro 158 million, equivalent to Rs.1,740 crore, which will be paid in cash upon closing.

Interestingly, the size of the transaction is nearly 50% of the current market capitalization of Gujarat Themis Biosyn, which stands at Rs.3,...